Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations

Chun-Nin Lee; Hsiang Yin Chen; H. Eugene Liu

doi:10.1200/JCO.2009.24.0747

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations

Chun-Nin Lee, Hsiang Yin Chen, H. Eugene Liu

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e111-ee112
Journal	Journal of Clinical Oncology
Volume	28
Issue number	7
DOIs	https://doi.org/10.1200/JCO.2009.24.0747
Publication status	Published - Mar 1 2010

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2009.24.0747

Cite this

@article{02ca571751ea4fb4b41804b0de2b382b,

title = "Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations",

author = "Chun-Nin Lee and Chen, {Hsiang Yin} and Liu, {H. Eugene}",

year = "2010",

month = mar,

day = "1",

doi = "10.1200/JCO.2009.24.0747",

language = "English",

volume = "28",

pages = "e111--ee112",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "7",

}

TY - JOUR

T1 - Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations

AU - Lee, Chun-Nin

AU - Chen, Hsiang Yin

AU - Liu, H. Eugene

PY - 2010/3/1

Y1 - 2010/3/1

UR - http://www.scopus.com/inward/record.url?scp=77949885180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949885180&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.24.0747

DO - 10.1200/JCO.2009.24.0747

M3 - Article

C2 - 20008635

AN - SCOPUS:77949885180

SN - 0732-183X

VL - 28

SP - e111-ee112

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 7

ER -

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this